Table Of Content

JAIDS Journal of Acquired Immune Deficiency Syndromes 31:547-550 © 2002 Lippincott Williams & Wilkins, Inc., Philadelphia Journal of Acquired Immune Deficiency Syndromes Volume 31, 2002 Author Index Abbate I, 488 Benson CA, 257 Cao C, 147 Aboulker J-P, 464 Bentwich Z, 56 Capitano B, $103 Abrams L, 399 Berhe N, 56 Capobianchi MR, 488 Abrescia N, S158 Berk ML, 367 Cappiello G, 488 Acero G, 147 Bernasconi E, 50 Cardenas PC, 348 Adorni F, 440 Berry MJ, 453 Carlson BA, 453 Agyingi L, 495, 506 Berry SH, 367 Carpenter CCJ, 378 Alden B, 154 Bertagnolio S, 38 Carr A, 257, 318 Aloisi MS, $145 Bettinger D, 276 Carrieri P, $149 Amendola A, 488 Bickel M, 171 Cass W, S62 Ammassari A, S95, $123, $128, $136, Biggar RJ, 536 Castelli F, $123 $140, S158 Biglione M, 348 Cauda R, 38, 545 Anderson E, $43 Biichlé S, 276 Cavalli B, 440 Anderson K, 237 Bindman AB, 202 Ceballos A, 348 Angeletti C, 488 Black D, 472 Ceccherini-Silberstein F, $118 Antinori A, 488, S95, $118, S123, Blair JM, 339 Celadilla ML, 348 $128, S136, S140, S158 Blanch J, 404 Chan K, 521 Antoni MH, S89 Blanco J-L, 404 Chan KJ, 250, 448 Arango JC, $35 Boccia S, 38 Chapin S, 299 Arici C, $145 Boggian K, 50 Chappey C, 128 Arreola R, 453 Booze RM, S62 Chave J-P, 50 Atkinson JS, 218 Bordi L, 488 Cheminot N, 299 Avila MM, 348 Bosfield E, 365 Chemlal K, 178 Boshoff C, 384 Bacchetti P, 171 Chesney M, 309, S149 Boubaker K, 50 Bacconier J, 115 Bouhnik A-D, $149 Chesney MA, S107 Back D, 45 Bourboulia D, 384 Chesson HW, 71 Badaro R, 399 Bozzette SA, 367 Chiodo F, 361 Baeten JM, 243 Brand R, 237 Ciappina V, 363 Bai Y, 147 Cingolani A, S118 Brathwaite CEM, 163 Balzano R, $145 Clair S, 276 Brebbia JS, 163 Bang H, 331 Clark RA, 543 Brettle RP, S35 Bangsberg DR, S107 Britton S, 56 Clouse KA, 453 Bankson DD, 243 Cohn SE, 367 Brodt HR, 171 Baratin D, 318 Brogan T, 106 Colasante C, 440 Bard E, 276 Brogly S, 98 Coley J, 331 Barthélémy C, 299 Bronstone A, $107 Collaborative Group, 318 Bartizal K, 183 Brown T, S70 Collazos J, 322 Bassignot A, 285 Bruneau J, 98 Collier AC, 318 Bassirou B, 106 Combs GF Jr, 453 Bruno R, 363 Basso S, 115 Combs T, 514 Brun-Vézinet F, 464 Bates M, 121, 128 Brust JCM, S29 Cooke M, 309 Beall G, 354 Cooper DA, 318 Budabbus MA, 488 Becker-Pergola G, 327 Cope A, 384 Burda S, 495, 506 Bélec L, 106 Bwayo JJ, 243 Coull JJ, 45 Bell DC, 218 Cozzi-Lepri A, S118, S140 Bell JE, S35 Calvez V, 384 Craib KJ, 117 Bellocchi MC, $118 Calza L, 361 Creasman JM, 291 Bennett KK, 20 Campa A, S84 Cross A, 399 547 548 AUTHOR INDEX Currier J, 354 Gabe R, 391 Hauser KF, $62 Currier JS, 257, S1, S16 Gail MH, 536 Havlir DV, 20 Galai N, 56 Hawken MP, 529 Gallais H, $149 Hayes P, 384 D’Arminio Monforte A, $118, $123, Galli M, 440, S140 Heath KV, 211 S158 Garcia-Fructuoso MT, 450 Hecht FM, 202, S107 d’Arminio Monforte A, $128, $136, Garzaniti A, 363 Hellmann NS, 121, 128 $140, $145 Gataric N, 117 Helm M, 137 Dallabetta G, 529 Gatell J-M, 404 Hemalatha R, 378 de Dieu Longo J, 106 Gathe J Jr, 399 Henson C, 416 De Lazzari E, 404 Gazzard B, 384 Herndier BG, 171 De Longis P, $136 de Los Angeles Pando M, 348 Gazzaruso C, 363 Hertzmark E, 331 Gebhardt J, 154 Heyndrickx L, 495 De Luca A, S118 Gelato MC, 163, 514 Hicks PS, 183 De Maddalena C, 440 Gendelman HE, S43 Hilton C, 416 de Truchis P, 178 George SL, 154 Hilton M, 416 DeGruttola VG, 20 Descamps D, 464 Gerber JG, 257 Hirschel B, 50, 318 Gevorkian G, 147 Hoadley D, 365 Devidas A, 178 Giammarioli AM, 545 Hogg RS, 117, 211, 448, 521, S122 DiNubile MJ, 183, 478 Gibson DR, 237 Holte S, 432 Dobs A, S70 Gifford AL, $163 Hossain MM, 45 Donahoe RM, S78 Gill J, 384 Huang L, 291 Dorenbaum A, 309 Gillibert R-P, 318 Hughes MD, 121 Drobacheff C, 276 Giordanetti S, 363 Hunter D, 331 Dubé MP, 257 Girardi E, 488, S145 Durand A, 115 Gladyshev VN, 453 Ibarra S, 322 Glatt AE, 542 Ickovics JR, S98 Edinburgh KJ, 291 Glidden D, 309 Ippolito G, 488, S145 Eisdorfer C, S89 Glynn JR, 80 Islam R, 27 Eljhawi OA, 488 Goedert JJ, 536 Izopet J, 464 Engels EA, 536 Goldie SJ, 27 Izzo C, $136 Eron JJ Jr. 11 Go6mez-Roman VR, 147 Jacchetti G, 440 Escaut L, 299 Gonzales MJ, 285 Eshleman SH, 327 Gonzalez M, 251 Jackson JB, 327 Jacobson MA, 472 Essex M, 331 Gonzalez-Cuevas A, 450 Gonzalez-Santos P, 251 Janssen R, 188 Jardel C, 299 Fabry J, 318 Gorbach SL, 230 Jasmer RM, 291 Fadda G, 38 Gori C, S118 Jeang K-T, 453 Gotch F, 384 Farrell B, 365 Gotway MB, 291 Jensen EH, 478, 483 FFaaswazni MW,, 434301 Grant RM, 171 JJoolhlnys oPn, 4D0F8, 354 Fernyak SE, 63 Graves A, 422 Joly V, 464 Fields KH, 453 Greenberg AS, | Jones LE, 369 Filice G, 363, S145 Grésenguet G, 106 Jordan W, 354 Finn TS, 478. 483 Grimm TA, 453 Juncosa T, 450 Fisch] MA, 478 Grimwood A, 399 Junghans C, 50 Grinspoon SK, 257 Flandre P, 464 Flanigan TP, 378 Gripshover B, 119 Kahn JG, 237 Fleming PL, 339 Groessl EJ, $163 Kapiga S, 331 Fleming T, 327 Gross M, 432 Karita E, 408 Flepp M, 50 Grunfeld C, 257 Karon J, 188 Guarinieri M, S167 Forbici F, S118 Karon JM, 339 Force G, 178 Guay LA, 327 Kartsonis N, 183 Forrester J, 230 Guydish J, 237 Katner HP, 483 Fortuny C, 450 Katz MH, 63 Foster MB, 154 Haensel A, 50 Katzenstein DA, 121 Francis H, $27 Hahn JA, 422 Kellerman SE, 202 Frank I, $10 Harel M, 464 Kellogg TA, 63 Freedberg KA, 27 Harrer T, 137 Kendall MA, 543 Frisch M, 536 Harris M, 250, 448 Kenfack H, 495, 506 Fuhrer J, 163 Hatfield DL, 453 Kerr T, 117 Furrer H-J, 50 Haughey NJ, S55 Kewn S, 45 JAIDS Journal of Acquired Immune Deficiency Syndromes, Vol. 31, No. 5, December 15, 2002 AUTHOR INDEX Khalsa JH, S27 Manoutcharian K, 147 Nadas A, 506 Khayam-Bashi H, 472 Maragos W, S62 Nadler JP, 483 Kimmel AD, 27 Marcelin A-G, 384 Nanfack A, 495, 506 Kitchen VS, 391 Margolick JB, 416 Nappa S, S158 Klein JD, 367 Margolis DM, 45 Napravnik S, 11 Klesczewski K, 399 Mariam ZG, 56 Narciso P, $123 Klinzman D, 154 Marmor M, 432, 506 Nasti G, $140 Knox TA, 230 Maroldo L, 128 Nath A, S62 Koblin B, 432 Marquez M, 251 National Institute of Mental Health Komaroff E, 514 Marschner IC, 20 Multisite HIV Prevention Trial Korn K, 137 Martin JN, 472 Group, 71 Kotler DP, 257 Martindale SL, 521 Ndinya-Achola JO, 243 Kowalczyk J, 408 Martinez E, 322, 404 Ndonko F, 506 Kreiss JK, 243 Martinez M, 348 Nelson KE, 416 Kumar AM, S89 Marx PA, 453 Neuenburg JK, 171 Kumar M, S89 Maserati R, 363 Ng V, 472 Kumarasamy N, 378 Ng’ang’a LW, 529 Massetto B, 440 Kumwenda NI, 90 Matarrese P, 545 Ngombo DT, 529 Kutza J, 453 Mathys J-M, | Nibarere J-A, 408 Mattson MP, S55 Nkombe I, 506 Lacarelle B, 115 Mayaan S, 56 Noto P, $123, $145 Lacey CJ, 391 Mayer KH, 378, 432 Nunn AJ, 391 Ladisa N, $128 Mayo J, 322 Nyambi P, 495, 506 Laibe S, 276 Mazzotta F, S140 Landay A, 56 Mbah H, 506 Langan SJ, 416 McClelland RS, 243 O'Connell JM, 521 Lankford-Turner P, S78 McCormack S, 391 O’Shaughnessy MV, 98, 211 Lansky A, 202 McFarland W, 63 Obadia Y, S149 Lastere S, 464 McLaren C, 399 Ochoa K, 422 Latorre C, 450 McLean N, 521 Opravil M, 50 Lauenroth-Mai E, 253 MeNurlan MA, 163, 514 Orofino G, $158 Lavreys L, 243 Meade CS, S98 Oroszlan S, 453 Layde PM, 71 Mechali D, 178 Osio M, 440 Lecusay R, S84 Mehabresh MI, 488 Overbaugh J, 243 Lederman M, 119 Meiffrédy V, 464 Leen C, $35 Meillet D, 276 Lehman JS, 202 Melis RDJ, 529 Paar DP, 483 Lenderking WR, 432 Melzi S, S128 Page-Shafer K, 63 Lester P, 309 Menichetti F, $145 Palacios R, 251 Levin J, 365 Mera R, 365 Palmer S, 285 Liberatore D, 348 Miguez-Burbano M-J, S84 Paltiel AD, 27 Liomba GN, 90 Milinkovic A, 404 Parkin N, 128 Lombes A, 299 Millon L, 276 Paterson DL, S103 Losina E, 27 Mmiro F, 327 Patrick KD, 154 Low P, 137 Moatti J-P, S149 Perales D, 237 Low-Beer N, 391 Montaner JSG, 211, 250, 448 Peralta LM, 348 Lu S, 354 Montaner JSG, $112 Perelson AS, 369 Lubin JH, 536 Montoya ID, 218 Perez B, 309 Lum PJ, 422 Morales G, S84 Perez-Cuevas J-B, 404 Moreau J, $149 Peri J-M, 404 Madden JJ, S78 Moroni M, 440 Perno CF, S118 Maenza J, 318 Moss A, 422 Perrin L, 318 Maffezzini E, 363 Mracna M, 327 Petropoulos CJ, 128 Mahajan AP, 378 Msamanga G, 331 Petru A, 309 Maisonobe T, 299 Mulligan K, 257 Petruschke RA, 483 Malkin J-E, 106 Munoz-Almagro C, 450 Peytavin G, 464 Malorni W, 545 Mura MS, S128 Pfaller MA, 154 Mamet J-P, 178 Murri R, $123, $136, S158 Piano P, S118 MANIF2000 Study Group, $149 Musoke P, 327 Pinkerton SD, 71 Mandaliya K, 243 Mussini C, $158 Piscopo R, S145 Mandaliya KN, 529 Mwatha A, 327 Poizot-Martin I, 115 Manfredi R, 361 Mynarcik DC, 163, 514 Poole C, 11 JAIDS Journal of Acquired Immune Deficiency Syndromes, Vol. 31, No. 5, December 15, 2002 550 AUTHOR INDEX Posteraro B, 38 Selnes OA, $132 Valleroy L, 188 Potoski B, $103 Shafer KP, 422 Vanhems P, 318 Powderly WG, 257, S3 Shafer RW, 121, 285 Vecchiet J, $123 Praindhui D, 178 Shang J, 495, 506 Visco-Comandini U, 488 Prendergast M, S62 Shanmugam I, 453 Vittecoq D, 299 Press N, $112 Shaw LM, 45 Vizzard J, 318 Price J, 529 Shor-Posner G, S84 Vora S, 318 Price RW, 171 Shulman NS, 121 Vuitton D, 285 Pulik M, 178 Sighinolfi L, $128 Vullo V, S118 Simmonds P, $35 Vyankandondera J, 408 Quan VMinh, 188 Simon PA, 354 Quick JL, 163 Singer J, 211 Waldrop D, S89 Quinn TC, 416 Siriarayapon P, 80 Walensky RP, 27 Quinson A-M, 115 Skolnik PR, | Walter H, 137 Solas C, 115 Wang Y, S78 Rabbi MF, | Solomon S, 378 Wara D, 309 Randall Lanier E, 45 Southwell H, 119 Wax MR, 163 Ravaux I, 115 Spiegelman D, 230, 331 Webb WR, 291 Remis R, 521 Spire B, S149 Weber R, 50 Renjifo B, 331 Spittal P, 98 Weiner D, 147 Richardson BA, 243 Squires K, S24 Weinstein MC, 27 Richman DD, 20 Stapleton JT, 154 Weinstock H, 188 Rickenbach M, 50 Starace F, $136 Weiss R, 309 Ridolfo AL, $140 Steigbigel RT, 163 Welker Y, 178 Robertson R, $35 Steketee RW, 188 Wener MH, 243 Robinson WR, 543 Sternberg D, 299 Whalley P, 309 Rosenberg FM, 448 Stevens MR, 202 Whitcomb JM, 121 Rousaud A, 404 Strathdee SA, 521 Wilkinson J, 384 Routy J-P, 318 Sutcliffe S$, 90 Willoughby B, 521 Rouveix E, 178 Swiss HIV Cohort Study, 50 Wilson HM, 478, 483 Royal W III, S27 Winters MA, 121 Ruiz J, 251 Tacconelli E, 38 Wise H, 45 Ryan D, 183 Taha TE, 90 Wohl AR, 354 Tamalet C, 464 Wojna V, S62 Saag MS, 257 Tang AM, 230 Wolday D, 56 Sable CA, 183 Taylor E, 90 Wood E, S112 Sabundayo BP, 416 Tchetgen E, 230 Wortley PM, 202 Sacchi P, 363 Telenti A, 50 Wu AW, S95, S123, $136, S140, S154, Saddi VR, 542 Temmerman M, 529 S158 Salihu H, 408 Tesiorowski AM, 250, 448 Santamaria H, 147 Thomas JC, 11 Xiong H, S43 Santambrogio S, 440 Thompson CR, 250 Xu X-M, 453 Santos J, 251 Thyagarajan SP, 378 Sax PE, 27 Tongo M, 495, 506 Yan CC, 448 Scalzini A, $136 Touraine J-L, 318 Yanai H, 80 Scasso A, S118 Trépo C, 318 Yang S-J, 218 Schambelan M, 257 Trotta MP, S118, $123, $128, S136, Yanpaisarn S, 80 Schechter MT, 98 $140 Yéni P, 464 Scherer PE, 514 Tschochner M, 137 Ylisastigui L, 45 Schlote F, 253 Tuldra A, S154 Young B, 478 Schlote W, 171 Tumbarello M, 38 Schmidt B, 137 Turchan JT, S62 Zaccarelli M, $128 Schmidt WN, 154 Turner D, 45 Zehender G, 440 Schmitt M, 137 Tyndall MW, 98, S112 Zekeng L, 495, 506 Schneiderman N, S89 Zeldin RK, 478, 483 Schwarzberg F, 365 Uberla K, 137 Zeng A-F, 464 Schwingel E, 137 Ugen KE, 147 Zhang H, 27 Seage GR III, 27, 432 Urbanski M, 495 Zhong P, 495, 506 Seboxa T, 56 Uthaivoravit W, 80 Zink W, S43 Séhonou J, 106 Zocchetti C, 363 Seillés E, 276 Valdez H, 119 Zolla-Pazner S, 495, 506 Sékaly R-P, 318 Valdivielso P, 251 Zolopa AR, 121 JAIDS Journal of Acquired Immune Deficiency Syndromes, Vol. 31, No. 5, December 15, 2002 JAIDS Journal of Acquired Immune Deficiency Syndromes 31:551-561 © 2002 Lippincott Williams & Wilkins, Inc., Philadelphia Journal of Acquired Immune Deficiency Syndromes Volume 31, 2002 Subject Index A/G recombinant HIV-1, underevaluation of plasma viral of HAART, 322, S3 load in cluster of patients infected with, 488 of long-term HAART, S24 Abacavir in nonadherence to antiretroviral therapy, 211 efficacy and safety of in combination regimen, 178 AF487122-AF487139, evolution of in HIV-1-infected mycophenolate and in depleted intracellular deoxyguano- couples, 285 sine triphosphate, 45 Africa Acceptance rate, of voluntary HIV counseling and testing HIV-1 group M clades in rural population of, 495 among pregnant women in Rwanda, 408 HIV infection in rural population of, 506 Acrp30 levels, in HIV-infected subjects with insulin resis- HIV transmission through breastfeeding in, 331 tance and body fat redistribution, 514 opportunity for prevention of HIV and STIs in youth of, ACTG 076 protocol, efficacy of in reducing mother-to-child 529 transmission, 348 survival of infants with HIV-1 subtypes A and D, 327 Acute phase response, vitamin A status and among HIV-1- vitamin A status and acute phase response among HIV-1- infected women in Kenya, 243 infected women in, 243 Acute retroviral syndrome, clinical features of by route of voluntary HIV counseling and testing among pregnant infection, 318 women in labor in, 408 Adherence voluntary HIV testing and counseling among sexually ac- to antiretroviral therapy, S95 tive population in, 106 adipose tissue alterations and, $140 African American men, risk behaviors among, 354 among injection drug users, $149 Age, clinical features of acute retroviral syndrome and, 318 behavioral correlates of, S98, S145 AIDS, assessing role of selenium in, 453 biomedical sciences in, S98 AIDS dementia computer-assisted self-interviewing to improve provider drug abuse in, S62 assessment of, S107 neuroprotection in, S84 immunologic response and clinical progression in, $112 tat and gp120 proteins in, $55 interventions to improve, S154 AIDS progression measurement of, $103 in adherence to HAART, S112 neurocognitive aspects of, $132 increased risk of with HTLV-2/HIV-1 coinfection, 440 patient self-management and, S163 severity of acute retroviral syndrome and, 318 patient’s point of view in, S167 AIDS surveillance data, among racial/ethnic minority men physician estimates of, S158 who have sex with men, 339 virologic correlates of, $112, S118 AIDSVAX B/B trial, willingness to participate and enroll in, determinants of, S98 521 factors affecting, in once-daily highly active antiretroviral Alcoholism, HIV infection and, S62 therapy, S10 Alpha-tocopherol, for HIV-infected drug abusers, S84 to HAART, S24 Alternative therapy, in HIV-infected patients at urban tertiary correlates and predictors of, $123 care center (letter), 119 depression and, $136 Alveolar macrophages, peroxisome proliferator-activated re- treatment-related factors and, $128 ceptor stimulation in HIV-1 replication and tumor Adiponectin levels, in HIV-infected subjects with insulin necrosis factor <Itga production in, | resistance and body fat redistribution, 514 Alzheimer disease Adipose tissue changes, in adherence to HAART, S140 antioxidant therapy for, S84 Adolescents, progression of cervical disease among with low- HIV-1 tat and gp120 proteins in, S55 grade squamous intraepithelial lesions (letter), 543 Amprenavir, lopinavir/ritonavir interaction with in salvage Adult day program, impact of on hospital utilization by therapy (letter), 115 HIV/AIDS patients (letter), 117 Anaerobic threshold, in HIV-positive patients on antiretrovi- Adverse effects ral therapy (letter), 250 of antiretroviral drugs, 50 Animal model, in assessing role of selenium in AIDS, 453 552 SUBJECT INDEX Anti-HIV-1 gp120 murine monoclonal antibody, phage-dis- Anxiety, factors related to pediatric HIV diagnosis and, 309 played mimotopes recognizing, 147 Argentina, efficacy of strategies to reduce mother-to-child Antibody-dependent cellular cytotoxicity (ADCC) antibody, HIV-1 transmission in, 348 phage-displayed mimotopes recognizing, 147 Astrocytes, in HIV-1-associated dementia, $43 Antibody-negative hepatitis C virus, HIV-related, 154 At-risk populations, HIV testing within, 202 Anticholinergics, neurologic complications with use of, S29 Attitudes, toward HIV testing within at-risk populations, 202 Antimotivational syndrome, with marijuana abuse, $29 Autopsy, HIV-related neuropathology in with HAART treat- Antioxidants ment, 171 for HIV-associated dementia, S62 Azole resistance, Candida strains and, 38 for HIV-positive drug users, $84 Antiretroviral therapy abnormal body fat distribution with, 50 B-lymphocyte function, long-term HAART effect on, 472 adherence to, S95 Bacterial pneumonia, clinical and radiographic predictors for, adipose tissue alterations and, S140 291 among injection drug users, S149 Barbiturates, neurologic complications of chronic use of, S29 behavioral and biomedical sciences in, S98 Basal ganglia, AIDS-related neuronal apoptosis in, $55 behavioral correlates of, $145 Bayer Versant, underevaluation of HIV-1 plasma viral load computer-assisted self-interviewing to improve provider with, 488 assessment of, $107 Behavior, in adherence to antiretroviral therapy, $145 correlates and predictors of, $123 Behavioral changes, as markers of sexually transmitted dis- depression and, $136 ease risk reduction in HIV prevention trials, 71 interventions to improve, S154 Behavioral sciences, in understanding adherence to antiretro- neurocognitive aspects of, $132 viral therapy, S98 patient self-management and, $163 Biological models, in predicting spread of HIV infection, 218 patient’s point of view in, S167 Biological parameters, in measuring adherence to antiretrovi- physician estimates of, S158 ral therapy, $103 treatment-related factors and, $128 Biomedical sciences, in understanding adherence to antiretro- virologic correlates of, S118 viral therapy, S98 adverse effects of and nonadherence, 211 Birth defects, with substance abuse, $29 anaerobic threshold and random venous lactate levels with Bisexual men (letter), 250 HIV risk behaviors among, 354 art of, S3 willingness of to participate and enroll in phase 3 preven- baseline predictors of CD4 T-lymphocyte recovery with, tive HIV-1 vaccine trial, 521 20 Blood-brain barrier, HIV-1 penetration of, S43 benefits and challenges of, S1 Blood cells, peroxisome proliferator-activated receptor stimu- Candida strains and resistance to, 38 lation in HIV-1 replication and tumor necrosis factor cardiovascular risks of, S16 <Itga production in, | dosing and tolerability problems of, S24 Body cell mass, survival and in HIV-positive patients, 230 in drug abusers, $43 Body fat distribution effects of on Kaposi sarcoma-associated herpesvirus infec- abnormalities of with antiretroviral drugs, 50 tion, 384 adiponectin and leptin levels with, 514 efficacy and safety of fenofibrate for hypertriglyceridemia improved with rosiglitazone treatment, 163 associated with (letter), 251 Bone disease, in HIV-infected injection drug users, S70 efficacy and safety of in combination regimen, 178 Brain enteric-coated, 399 AIDS-related neuronal apoptosis in, S55 evolution of resistance to in HIV-1-infected couples, 285 cytomegalovirus infection of with HAART treatment, 171 lipodystrophy with, 404 HIV infection and drug abuse effects on, S62 measurement of adherence to, $103 Breastfeeding, HIV transmission through in Tanzania, 331 metabolic complications associated with, management of, 257 mitochondrial damage with long-term use of, 299 C-reactive protein, vitamin A status and among HIV-1-in- mycophenolate added to, 45 fected women in Kenya, 243 nucleoside-based, HIV-associated lipodystrophy syndrome Calcium dysregulation, by HIV-1 tat and gp120 proteins, S55 with (letter), 253 Cameroon persistent multidrug resistance to after treatment interrup- HIV-1 group M clades in rural population of, 495 tion, 137 HIV infection in rural population of, 506 projecting outcomes of, 27 Canada, needle exchange programs among injection drug random venous lactate levels with (letter), 448 users in, 98 sexual dysfunction with, 322 Cancer, risk for in AIDS, 536 weight loss and survival with, 230 Candida strains, azole susceptibility patterns and, 38 zidovudine resistance mutations and virologic response to, Candidiasis 464 esophageal, efficacy of caspofungin for, 183 JAIDS Journal of Acquired Immune Deficiency Syndromes, Vol. 31, No. 5, December 15, 2002 SUBJECT INDEX oral Cognitive impairment azole susceptibility patterns and, 38 in adherence to antiretroviral therapy, $132 nonspecific secretory immunity with, 276 of HIV-1-associated dementia, $43 Cardiovascular risks Coinfection, increased risk of developing peripheral neuropa- with high prevalence of metabolic syndrome among HIV- thy with, 440 infected patients (letter), 363 Combination antiretroviral therapy of highly active antiretroviral therapy, S16 baseline predictors of CD4 T-lymphocyte recovery with, Case-control study, of evolving epidemiology of HIV and 20 tuberculosis in northern Thailand, 80 clinical trials of, 399 Case-crossover study, of partner and situational factors for zidovudine resistance mutations and virologic response to, unprotected sex, 432 464 Caspofungin, efficacy of for esophageal candidiasis resistant Combivir, efficacy and safety of in combination regimen, to fluconazole, 183 178 Catecholamines, in HIV-infected drug abusers, S89 Communication, in adherence to antiretroviral therapy, S158 CD4 count, in timing opportunistic infection prophylaxis in Complementary medicine therapies, use of among HIV-in- resource-constrained countries, 378 fected patients at urban tertiary care centers (letter), CD4 T-lymphocytes, baseline predictors of recovery with 119 combination antiretroviral therapy, 20 Compliance Cell-mediated immunity, long-term HAART effect on resto- to HAART, correlates and predictors of, $123 ration of, 472 interventions to improve, $154 Central African Republic, voluntary HIV testing and counsel- patient-physician relationship and, S158 ing among sexually active population in, 106 patient self-management and, $163 Central nervous system Computed tomography, in intrathoracic lymphadenopathy effects of drug abuse and HIV infection on, S35 diagnosis, 29] HAART-related pathology of, 171 Computer-assisted self-interviewing HIV-1 infection of, $55 for adherence information, S95 Cervical disease, progression of among HIV-infected adoles- to improve provider assessment of adherence in routine cents with low-grade squamous intraepithelial lesions clinical practice, S107 (letter), 543 Continuous antiretroviral therapy, projecting outcomes of, 27 Chemokines, in HIV-1-associated dementia, $43 Coronary heart disease risk, of highly active antiretroviral Children therapy, S16 absence of detectable HIV-1 provirus DNA in after early Counseling, anonymous, risk behaviors and HIV incidence at HAART (letter), 450 sites for, 63 efficacy of strategies to reduce HIV-1 transmission to in Cytokines, in HIV-1-associated dementia, S43 Argentina, 348 factors in adherence to HAART among, S112 factors related to timing of diagnostic disclosure and emo- Delayed therapy, projecting outcomes of, 27 tional distress in, 309 Dementia, HIV-associated Chronic disease, self-management of and adherence to HIV drug abuse and, S62 medications, $163 with HIV-1 infection, $43 Circulating recombinant form (CRFO2), underevaluation of HIV-1 tat and gp120 proteins in, S55 HIV-1 plasma viral load in cluster of patients infected neuroprotection in, S84 with, 488 Deoxyguanosine triphosphate, depleted intracellular, myco- Clinical practice, computer-assisted self-interviewing to im- phenolate added to antiretroviral therapy and, 45 prove assessment of adherence in, $107 Depression, in suboptimal adherence to HAART, S136 Clinical progression, in adherence to HAART, S112 Developing countries, timing opportunistic infection prophy- Clinical support, for once-daily highly active antiretroviral laxis in, 378 therapy, S10 Deworming, decreased HIV plasma viral load and, 56 Clinical trials Dextrin sulfate, as vaginal microbicide, 391 of combination antiretroviral therapy in CD4 T-lympho- Diagnosis, of pediatric HIV-1 infection, 348 cyte recovery, 20 Diagnostic disclosure, factors related to timing of, 309 of combination combivir-abacavir-efavirenz regimen, 178 Diarrhea, Clostridium difficile-associated in HIV patients of enteric-coated didanosine, stavudine, and nelfinavir ver- (letter), 542 sus zidovudine plus lamivudine and nelfinavir, 399 Didanosine, enteric-coated, 399 Clostridium difficile-associated diarrhea, in HIV patients (let- Dilution bias, in estimating HIV risk behavior with use of ter), 542 syringe exchange, 237 Cocaine Disease progression, vaccination effects on, 369 interaction of with HIV infection, S62 DNA, mitochondrial, antiretroviral therapy-related damage neurologic complications with use of, $29 to, 299 Cognitive dysfunction DNA repair, reduced capacity for in HIV-infected lympho- with AIDS dementia, $55 cytes of opiate addicts, $78 antioxidant therapy for, $84 Dopamine, interaction of with HIV infection, S62 JAIDS Journal of Acquired Immune Deficiency Syndromes, Vol. 31, No. 5, December 15, 2002 554 SUBJECT INDEX Dosing frequency, in adherence to HAART, S128 Epidemiolog Dosing issues, for highly active antiretroviral therapy, $24 of hepatitis C virus in AIDS, 536 Dosing rationale, in once-daily highly active antiretroviral of HIV infection and tuberculosis in northern Thailand, 80 therapy, S10 in United States from 1978-1999, 188 Drug abuse Epitope mapping, of ADCC antibody, 147 in adherence to antiretroviral therapy, S145 Erratum in Edinburgh cohort of HIV-infected individuals, S35 “A protocol for the analytical aspects of a systematic re- in HIV-1-associated dementia, $43 view of HIV prevention research” (2002;30(suppl 1): HIV infection interaction with, S62 $62-S72), 368 metabolic disorders with in HIV-infected individuals, S70 “Injection-related risk behaviors in young urban and subur- neurologic complications of, S35 ban injection drug users in Chicago (1997—1999)” neuroprotection for HIV infection with, S84 (2001;27:71-78), 255 Drug addiction, in Edinburgh cohort of HIV-infected indi- Esophageal candidiasis, efficacy of caspofungin for, 183 viduals, $35 Estrogen, for HIV-associated dementia, $62 Drug interactions, between lopinavir and amprenavir in sal- Ethanol vage therapy (letter), 115 interaction of with HIV infection, S62 Drug resistance neurologic complications with use of, S29 in adherence to antiretroviral therapy, S107, S118 Etiology, clinical and radiographic predictors for in intratho- after treatment interruption, 137 racic lymphadenopathy, 291 evolution of in HIV-1-infected couples, 285 phenotypic and genotypic assays for, 128 virologic response to combination therapy and, 464 Fat distribution, abnormalities of with antiretroviral drugs, 50 in zidovudine-experienced patients, 121 Fat-free mass, survival and in HIV-positive patients, 230 Drug side effects, in adherence to HAART, S128, S140 Fat mass, survival and in HIV-positive patients, 230 Drug toxicity, in mitochondrial damage, 299 Fat redistribution Drug users, HIV-infected with HIV infection in injection drug users, S70 decreased HIV risk behavior with use of syringe exchange, 237 peroxisome proliferator-activated receptor stimulation and, l hepatitis C virus coinfection in, 154 HIV risk behaviors among, 354 Female-controlled methods, of HIV prevention, dextrin sul- HPA axis activity in, S89 fate in, 391] incidence among in United States from 1978-1999, 188 Fenofibrate metabolic disorders in nervous system damage to, $27 efficacy and safety of for antiretroviral therapy-associated neurologic complications in, $29 hypertriglyceridemia (letter), 251 Dyslipidemia in HIV-1 replication in peripheral blood mononuclear with highly active antiretroviral therapy, S16 cells, | in HIV-infected injection drug users, $70 Fetal defects, with substance abuse, $29 Fitness, in adherence to antiretroviral therapy, S118 Fluconazole-resistant Candida, efficacy of caspofungin for, Ecstasy, neurologic complications of, S29 183 Edinburgh cohort, HIV and drug misuse in, $35 Efavirenz, efficacy and safety of in combination regimen, 178 Efficacy Gay men of caspofungin for esophageal candidiasis resistant to flu- AIDS incidence and survival trends of among racial and conazole, 183 ethnic minorities, 339 of combination combivir-abacavir-efavirenz regimen, 178 HIV incidence among in United States from 1978-1999, of fenofibrate for antiretroviral therapy-associated hypertri- 188 glyceridemia (letter), 251 using injection drugs, prevalence and correlated of HIV of strategies to reduce mother-to-child HIV-1 transmission among, 422 in Argentina, 348 willingness of to participate and enroll in phase 3 preven- Electronic monitoring devices, in measuring adherence to tive HIV-1 vaccine trial, 521 antiretroviral therapy, $103 Gender differences Emotional distress, factors related to pediatric HIV diagnosis clinical features of acute retroviral syndrome and, 318 and, 309 in HIV RNA levels, 11 Encephalopathy, of HIV-1-associated dementia, $43 Genetics, in azole resistance of Candida strains, 38 Endocrine disorders, in HIV-infected injection drug users, Genotypic drug resistance assays, in HIV-1 infection, 128 S70 Glucocorticoids, in HIV-infected drug abusers, S89 Enhanced treatment, with twice-daily indinavir/ritonavir regi- Glucose abnormalities, in HIV-infected injection drug users, men, 483 $70 Enteric-coated antivirals, clinical trials of, 399 Glutamate uptake, HIV-1 Tat and gp120 proteins effects on, Epidemiologic methods, in case-crossover study of partner S55 and situational factors for unprotected sex, 432 Gonadal hormones, for HIV-associated dementia, $62 JAIDS Journal of Acquired Immune Deficiency Syndromes, Vol. 31, No. 5, December 15, 2002 SUBJECT INDEX gp120 protein, calcium dysregulation and neuronal apoptosis efficacy and safety of in combination regimen, 178 by, S55 immunologic and virologic issues in, $3 gp120-specific antibodies, phage-displayed mimotopes recog- increasing prevalence HIV encephalopathy with, 171 nizing, 147 lipodystrophy with, 404 long-term, restored B-lymphocyte function and, 472 Hallucinogens, neurologic complications with use of, S29 mitochondrial damage with long-term use of, 299 Health beliefs, toward HIV testing within at-risk populations, nucleoside-based, HIV-associated lipodystrophy syndrome 202 with (letter), 253 Health care, for HIV infection rural versus urban populations once-daily, S10 (letter), 365, 367 persistent multidrug resistance to after treatment interrup- Health services, for injection drug users in Canada, 98 tion, 137 Helminthic infection, with decreased HIV plasma viral load, regimens for, S1 56 selecting first treatment regimen in, S3 Hepatitis B virus, HIV-1 prevalence and among male work- sexual dysfunction with, 322 ers at sugar estate in Malawi, 90 subclinical hypothyroidism with (letter), 361 Hepatitis C virus timing for, S3 HIV-1 prevalence and among male workers at sugar estate weight loss and survival with, 230 in Malawi, 90 Hippocampus, AIDS-related neuronal apoptosis in, S55 prevalence of in AIDS, 536 HIV-1 group M clades, in rural population of Cameroon, 495 viremia of in HIV-related antibody negative infection, 154 HIV-1 infection Hepatocellular carcinoma, risk for in AIDS, 536 dementia of, $43 Herbal remedies, use of among HIV-infected patients at ur- neuroprotection in, S84 ban tertiary care centers (letter), 119 HPA axis in, S89 Heroin, interaction of with HIV infection, S62 lipodystrophy with, 404 Herpes simplex virus 2, HIV-1 prevalence and among male resistance testing in, 128 workers at sugar estate in Malawi, 90 transmission through breastfeeding in Tanzania, 331 Herpesvirus infection, Kaposi sarcoma-associated, antiretrovi- vitamin A status and acute phase response among women ral therapy effects on, 384 with, 243 Heteroduplex mobility analysis (HMA), of HIV-1 group M HIV-1 provirus DNA, absence of after early HAART in chil- clades in rural population of Cameroon, 495 dren (letter), 450 Heterosexual men, HIV risk behaviors among, 354 HIV-1 RNA, mycophenolate added to antiretroviral therapy Heterosexuals, HIV incidence among in United States from and reduction of, 45 1978-1999, 188 HIV-1 subtypes High-risk communities, HIV screening in, 416 survival of Ugandan infants with, 327 Highly active antiretroviral therapy (HAART) underevaluation of HIV-1 plasma viral load in, 488 absence of detectable HIV-1 provirus DNA after in chil- HIV-1 virus dren (letter), 450 mutation of with reduced DNA repair capacity in opiate adherence to, S95 addicts, S78 adipose tissue alterations and, S140 prevalence of among male workers at sugar estate in among injection drug users, $149 Malawi, 90 behavioral and biomedical sciences in, S98 replication of, peroxisome proliferator-activated receptors computer-assisted self-interviewing to improve provider in blocking of, | assessment of, S107 seroprevalence of in rural population of Cameroon, 506 correlates and predictors of, $123 transmission of, efficacy of strategies to reduce in Argen- depression and, $136 tina, 348 interventions to improve, $154 HIV/AIDS counseling, reasons for seeking or avoiding in measurement of, $103 at-risk populations, 202 neurocognitive aspects of, S132 HIV/AIDS risk model, social networks in, 218 patient’s point of view in, S167 HIV antibody testing, among rural population of Cameroon, treatment-related factors and, S128 506 virologic and immunologic response and clinical pro- HIV-associated lipodystrophy syndrome gression in, S112 adiponectin and leptin levels with, 514 art of, S3 with nucleoside-based HAART (letter), 253 benefits and challenges of, S1 HIV counseling, voluntary, among sexually active population Candida strains and resistance to, 38 in Central African Republic, 106 cardiovascular risks of, S16 HIV dementia, in adherence to antiretroviral therapy, $132 deferred, S3 HIV encephalitis dosing and tolerability problems of, S24 with injection drug use, $35 in drug abusers, $43 neurologic manifestations of, $43 early, advantages of, S3 tat and gp120 proteins in, S55 effects of on Kaposi sarcoma-associated herpesvirus infec- HIV encephalopathy, increased prevalence of with HAART, tion, 384 17] JAIDS Journal of Acquired Immune Deficiency Syndromes, Vol. 31, No. 5, December 15, 2002 556 SUBJECT INDEX HIV epidemic, evolving epidemiology of, 80 Infants, survival of with HIV-1 subtype A and D infections, HIV infection 327 in drug abusers, metabolic disorders in nervous system Infection, with parenteral substance abuse, $29 damage to, $27 Inhalants, neurologic complications with use of, $29 with drug addiction in Edinburgh cohort, $35 Injection drug users incidence of in United States from 1978-1999, 188 decreased HIV risk behavior with use of syringe exchange, molecular basis for interactions with abused drugs, S62 237 HIV plasma viral load, decreased with intestinal worm treat- factors in adherence to HAART among, S112 ment, 56 HIV and hepatitis C virus coinfection in, 154 HIV-related antibody negative hepatitis C virus infection, HIV encephalitis in, $35 viremia in, 154 HIV incidence among in United States from 1978-1999, HIV RNA levels 188 with combination antiretroviral therapy, 20 HIV-infected gender difference in, 11 HPA axis activity in, S89 HIV subtypes, in rural population of Cameroon, 495 metabolic disorders in, S70 HIV testing HIV risk behaviors among, 354 in at-risk populations in United States, 202 needle exchange programs among, 98 risk behaviors and HIV incidence at sites for, 63 nonadherence among, S149 tuberculosis cases and, 80 prevalence and correlated of HIV among, 422 urine antibody testing in, 416 Insulin resistance voluntary adiponectin and leptin levels with, 514 among pregnant women in labor in Rwanda, 408 therapy-related, guidelines for management of, 257 among sexually active population in Central African Insulin sensitivity, in HIV-infected patients treated with rosi- Republic, 106 glitazone, 163 Hospital utilization, adult day program impact on (letter), International AIDS Society-USA Panel, recommendations for 117 managing metabolic complications of antiretroviral Host-related factors, in adherence to antiretroviral therapy, therapy, 257 S118 Interrupted treatment, projecting outcomes of, 27 HPA axis, in HIV-1 infection, S89 Interventions, to improve adherence to antiretroviral therapy, HTLV-2/HIV-1 coinfection, increased risk of developing $98, S154 peripheral neuropathy with, 440 Intestinal worms, with decreased HIV plasma viral load, 56 Hyperinsulinemic-euglycemic clamp, in improved insulin Investigational agents, in highly active antiretroviral therapy, sensitivity, 163 S3 Hyperlipidemia, therapy-related, guidelines for management of, 257 Hypertriglyceridemia, antiretroviral therapy-associated, effi- Kaposi sarcoma, antiretroviral therapy in herpesvirus infec- cacy and safety of fenofibrate for (letter), 251 tion associated with, 384 Hypogonadism, in HIV-infected injection drug users, S70 Kenya Hypothyroidism, subclinical, with HAART (letter), 361 opportunity for prevention of HIV and STIs in youth of, 529 vitamin A status and acute phase response among HIV-1- Immune reconstitution, long-term HAART effect on, 472 infected women in, 243 Immune system activation in HIV-1 infection, 369 in intestinal worm treatment, 56 L-deprenyl, for HIV-associated dementia, S62 Immunity, nonspecific secretory, with oral candidiasis, 276 Lactate, venous levels of with antiretroviral therapy (letter), Immunologic response, in adherence to HAART, S112 448 Immunology, in highly active antiretroviral therapy decisions, Lactic acidemia, therapy-related, guidelines for management S3 of, 257 Incidence Lactoferrin, in oral candidiasis, 276 HIV risk behaviors and, 63 Lamivudine social networks in predicting, 218 with zidovudine and nelfinavir, 399 trends in among racial/ethnic minority men who have sex zidovudine resistance mutations and virologic response to, with men, 339 464 in United States from 1978-1999, 188 Leptin levels, in HIV-infected subjects with insulin resistance India, timing opportunistic infection prophylaxis in, 378 and body fat redistribution, 514 Indinavir Letters to editor twice-daily regimen of Absence of detectable HIV-1 provirus DNA after early in HIV-infected adults failing protease inhibitor regi- HAART in children infected by vertical transmission, men, 483 450 in protease inhibitor-naive HIV-infected adults, 478 Anaerobic threshold and random venous lactate levels zidovudine resistance mutations and virologic response to, among HIV-positive patients on antiretroviral therapy, 464 250 JAIDS Journal of Acquired Immune Deficiency Syndromes, Vol. 31, No. 5, December 15, 2002